Paul Kniery, MD
Pediatrics · Bowling Green, KYNPI 1598791071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 296 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $979 and has fallen 80.3% since, to $192 in 2024. Among pediatrics clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$856
- GSK$723
- Novo Nordisk$597
- Lilly USA, LLC$359
- Pfizer$278
- AstraZeneca$201
- plus $1K from 23 others
Across 39 payments — averaging $21,831 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$380K
- Astrazeneca UK Limited$364K
- Acrotech Biopharma Inc.$89K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
What the payments were for
- Food & beverage$4,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $856 |
| GSK | 37 | $723 |
| Novo Nordisk | 60 | $597 |
| Lilly USA, LLC | 27 | $359 |
| Pfizer | 25 | $278 |
| AstraZeneca | 13 | $201 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $135 |
| Supernus Pharmaceuticals, Inc. | 8 | $114 |
| Ironshore Pharmaceuticals Inc. | 7 | $105 |
| Corium, LLC | 7 | $95 |
| Sanofi Pasteur Inc. | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Ultragenyx Pharmaceutical Inc. | 4 | $73 |
| Amgen | 4 | $63 |
| Merck | 5 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $50 |
| Cranial Technologies, Inc | 3 | $42 |
| Mannkind Corporation | 3 | $42 |
| Medtronic(2 entities) | 2 | $29 |
| Siemens Medical Solutions USA, Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Boehringer Ingelheim | 1 | $20 |
| Abbott | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,171 in reported general payments places this provider in the 95th percentile of 777 pediatrics providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 118 | $144,981 |
| FarxigaDapagliflozin Propanediol | 81 | $93,018 |
| OzempicSemaglutide | 53 | $51,285 |
| EliquisApixaban | 44 | $50,549 |
| JardianceEmpagliflozin | 28 | $29,284 |
| LinzessLinaclotide | 25 | $23,070 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $20,340 |
| TrulicityDulaglutide | 17 | $16,282 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $14,477 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $8,649 |
| XareltoRivaroxaban | 12 | $6,393 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,366 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,601 |
| MyrbetriqMirabegron | 12 | $5,009 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $4,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $359 | $161,263135 claims |
| AstraZenecaFarxiga, Symbicort | $201 | $99,38494 claims |
| Novo NordiskOzempic | $597 | $51,28553 claims |
| PfizerEliquis | $278 | $50,54944 claims |
| Boehringer IngelheimJardiance | $20 | $29,28428 claims |
| AbbVieLinzess, Synthroid | $856 | $24,62146 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $723 | $23,66640 claims |
| MerckJanumet | $62 | $8,64915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 777 pediatrics providers in Kentucky.
Other pediatrics in Bowling Green
- Sarah MayfieldBowling Green$5K
- Zahid FraserBowling Green$3K
- Jeffrey BitterlingBowling Green$3K
- Pippa Pinckley-StewartBowling Green$3K
- John SmithBowling Green$3K
- Sirish PalleHyden$89K
- Christian BerkhahnLouisville$85K
- Maurice AllgeierLouisville$38K
- Stanley BlockBardstown$34K
- Michael SimonNicholasville$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.